Drilldown: Medicines

Codeine (2)

Other values:

Search

None (13)

Other values:

Search

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

None (3) · Active metabolite of tramadol; mu-opioid agonist (1) · Extremely potent mu-opioid receptor agonist (1) · Highly potent mu-opioid receptor agonist (1) · Irreversible non-selective MAO inhibitor (3) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · Melatonin receptor agonist; 5-HT2C antagonist (1) · Mitragynine/7-hydroxymitragynine; mu-opioid partial agonist (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; fentanyl analogue (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Opioid receptor partial agonist/antagonist; toxic alkaloid (1) · Partial mu-opioid receptor agonist; alpha-2 agonist (1) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (6) · Potent serotonin reuptake inhibitor; also NRI (1) · Prodrug of morphine; mu-opioid receptor agonist (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · Reversible inhibitor of MAO-A (1) · Selective mu-opioid receptor agonist (1) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Serotonin reuptake inhibitor and 5-HT2A antagonist (1) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · Serotonin–norepinephrine reuptake inhibitor (2) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) · Ultra-short-acting mu-opioid agonist (1) · Weak SRI; primarily H1/D2/alpha antagonist (1) · '"`UNIQ--vote-00000019-QINU`"' Once-daily dosing is a clinical advantage over short-half-life NSAIDs'"`UNIQ--ref-0000001A-QINU`"'. (1)

None (46) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' (1) · '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' (2) · '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"', '"`UNIQ--vote-00000027-QINU`"', '"`UNIQ--vote-00000028-QINU`"' (1)

None (46) · 200-400 mg PO every 4-6 hours as needed. OTC max 1200 mg/day without provider direction; prescription max 3200 mg/day divided (1) · 25 mg (1) · 7.5 mg PO once daily; titrate to 15 mg daily if needed. Vivlodex 5 mg PO once daily, max 10 mg (1) · Acute gout: 50 mg PO TID until symptom relief, then taper; maximum 200 mg/day for 3-5 days. Rheumatoid arthritis / osteoarthritis: 25-50 mg PO BID-TID. Patent ductus arteriosus: 0.2 mg/kg IV, then 0.1-0.2 mg/kg every 12-24 hours for 2 doses (1) · Adult: 15–60 mg every 4 hours as needed. (1) · Osteoarthritis: 200 mg PO once daily or 100 mg BID. Rheumatoid arthritis: 100-200 mg PO BID. Acute pain: 400 mg loading, then 200 mg every 12 hours (1)

None (46) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · Capsules 25, 50 mg; ER capsules 75 mg; oral suspension 25 mg/5 mL; suppositories 50 mg; injection 1 mg/vial (PDA closure) (1) · Capsules 50, 100, 200, 400 mg; Elyxyb oral solution 25 mg/mL (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1) · Tablets 200, 400, 600, 800 mg; capsules 200 mg; oral suspension 100 mg/5 mL; chewable tablets 100 mg; injection 100 mg/mL (Caldolor) (1) · Tablets 7.5, 15 mg (Mobic); capsules 5, 10 mg (Vivlodex); oral suspension 7.5 mg/5 mL; injection 30 mg/mL (Anjeso) (1)

None (46) · 15 mg/day (oral); 30 mg IV once daily (Anjeso) (1) · 200 mg/d (1) · 200 mg/day (typical adult oral) (1) · 3200 mg/day (Rx); 1200 mg/day (OTC, without provider direction) (1) · 360 mg/day (1) · 400 mg/day for chronic indications; higher for short-term acute pain (1)

None (45) · intravenous (1) · intravenous (Caldolor (1) · intravenous (PDA closure only) (1) · NeoProfen) (1) · Oral (6) · PO (only formulation marketed in the US). (1) · rectal (1)

None (45) · 30-60 minutes (1) · 30-60 minutes (oral) (1) · 30-60 minutes (oral); rapid relief in acute gout (1) · 30–60 min (PO) (1) · Analgesic effect within hours; full anti-inflammatory effect over 1-2 weeks (1) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1)

None (45) · 12-24 hours (1) · 24 hours (once-daily dosing supported by long half-life) (1) · 4-6 hours (1) · 4-6 hours (IR); 24 hours (ER) (1) · 4–6 hours (1) · Chronic daily dosing (1) · Long (1)

None (45) · 15-20 hours'"`UNIQ--ref-00000020-QINU`"' (1) · 2-4 hours'"`UNIQ--ref-00000026-QINU`"' (1) · 2.5–3 hours (1) · 4-5 hours'"`UNIQ--ref-00000026-QINU`"' (1) · ~11 hours'"`UNIQ--ref-00000029-QINU`"' (1) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)

None (45) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · ~100% (oral)'"`UNIQ--ref-00000027-QINU`"' (1) · ~50% (highly variable) (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~80-100% (oral)'"`UNIQ--ref-00000027-QINU`"' (1) · ~89% (oral)'"`UNIQ--ref-00000021-QINU`"' (1) · ~99% (oral)'"`UNIQ--ref-0000002A-QINU`"' (1)

None (45) · Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning (fetal renal dysfunction, oligohydramnios); contraindicated from 30 weeks (risk of premature ductus arteriosus closure)'"`UNIQ--ref-00000022-QINU`"' (1) · Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning (fetal renal dysfunction, oligohydramnios); contraindicated from 30 weeks (risk of premature ductus arteriosus closure)'"`UNIQ--ref-00000028-QINU`"' (1) · Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning (fetal renal dysfunction, oligohydramnios); contraindicated from 30 weeks (risk of premature ductus arteriosus closure)'"`UNIQ--ref-0000002B-QINU`"' (1) · Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning; contraindicated from 30 weeks (risk of premature ductus arteriosus closure, which is paradoxically the basis of the neonatal PDA-closure indication)'"`UNIQ--ref-00000028-QINU`"' (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1)

None (45) · Rx-only (1) · Rx-only in US (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Over-the-counter|OTC]] in the US at ≤200 mg per tablet / ≤1200 mg/day; [[USLegal:Prescription only|Rx-only]] at higher strengths and indications (1) · [[USLegal:Prescription only|Rx-only]] in US (3)